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2,6-DISUBSTITUTED PIPERIDINES AS 
MODULATORS OF NICOTINIC 
ACETYLCHOLINE RECEPTOR MEDIATED 
NEUROTRANSMITTER RELEASE, UPTAKE 
AND STORAGE 
RELATED APPLICATIONS 
This application is a continuation-in-part of application 
Ser. No. 09/628,557 ?led Jul. 28, 2000 now US. Pat. No. 
6,455,543 Which claims priority under 35 U.S.C. § 119(e)(1) 
to provisional Application No. 60/146,144 ?led Jul. 30, 
1999. 
FIELD OF INVENTION 
The present invention relates to the use of the 2,6 
disubstituted piperidines, cis-2,6-di-trans-styrylpiperidine 
and trans-2,6-di-trans-styrylpiperidine, as modulators of 
nicotinic acetyl-choline receptor mediated neurotransmitter 
release, uptake and storage. The 2,6-disubstituted pip 
eridines of the present invention can be used for the treat 
ment of drug abuse and WithdraWal therefrom, as Well as for 
the treatment of eating disorders such as obesity, and other 
neuropathologies. 
BACKGROUND OF THE INVENTION 
Currently, drug discovery is focusing on neuronal nico 
tinic receptors (nAChRs) as novel targets for the develop 
ment of therapeutic agents for a Wide variety of central 
nervous system (CNS) diseases including, drug addiction, 
neuroendocrine, neuropsychiatric and neurological diseases, 
memory and learning disabilities, eating disorders, and the 
control of pain, as Well as cardiovascular and gastrointesti 
nal disorders. Nicotinic receptor antagonists have good 
potential as therapeutic agents, since they offer another 
means of modulating nicotinic receptor function. Nicotinic 
agonists rapidly desensitiZe these receptors, essentially 
inhibiting their function. Thus, inhibition of nicotinic recep 
tor function may be the action, Which confers clinical utility, 
indicating that nicotinic receptor antagonists could also be 
bene?cial in the treatment of diseases for Which nicotinic 
agonists are currently being developed. For example, schiZo 
phrenia and drug abuse have both been associated With 
hyperactivity of CNS dopaminergic systems, and inhibition 
of nicotinic receptors may be advantageous in reducing such 
hyperactivity. Furthermore, the availability of subtype 
selective nicotinic receptor antagonists Will be invaluable 
agents in both basic and clinical research, With regard to 
both the treatment and diagnosis of disease. Finally, 
subtype-selective antagonists Will de?ne the role of speci?c 
nicotinic receptor subtypes in both physiological function 
and disease states. 
The action of many neuropharmacologically therapeutic 
agents involve the modulation of dopamine (DA), norepi 
nephrine (NE) and serotonin (5-HT) release, uptake and 
storage Within its respective terminals in the central nervous 
system (CNS). Most neurotransmitters are stored in synaptic 
vesicles, Which are prominent features of nerve terminals. 
Concentration into vesicles appears to be responsible for 
maintaining a ready supply of neurotransmitter available for 
neuronal exocytotic release into the synaptic cleft. Vesicles 
also serve the role of protecting the neurotransmitter from 
metabolic breakdown. One transport site on the vesicle 
membrane is the vesicular monoamine transporter-2 
(VMAT2), Whose role is to transport transmitter from the 
cytosol into the synaptic vesicle. MethoxytetrabenaZine 
(MTBZ) has been used as a radiolabel to probe the interac 
tion of drugs With VMAT2. Once the neurotransmitter is 
released from the terminal into the synaptic space, it inter 
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acts With postsynaptic receptors and subsequently is taken 
back up into the terminal via the plasma membrane trans 
porter (e.g., the dopamine transporter, DAT and/or the 
serotonin transporter, SERT). Thus, transporter proteins 
modify the concentration of neurotransmitter in the cytosolic 
and vesicular storage pools, thereby having the ability to 
alter subsequent neurotransmission. 
SUMMARY OF THE INVENTION 
The present invention is directed to a method of treating 
an individual Who suffers from drug dependence or With 
draWal from drug dependence or Who suffers from a disease 
or pathology of the CNS. The method comprises of admin 
istering to the individual an effective amount of either 
cis-2,6-di-trans-styrylpiperidine or trans-2,6-di-trans 
styrylpiperidine or an analog thereof, including pharmaceu 
tically acceptable salts of such compounds thereof. As used 
Wherein, the term “effective amount” means an amount of a 
drug effective to reduce an individual’s desire for a drug of 
abuse or for food, or for alleviating at least one of the 
symptoms of the disease or pathological symptom of CNS 
pathology. 
The compound can be administered alone, combined With 
an excipient, or co-administered With a second drug having 
a similar or synergistic effect. The compound is adminis 
tered subcutaneously, intramuscularly, intravenously, 
transdermally, orally, intranasally, intrapulmonary or rec 
tally. The use of cis-2,6-di-trans-styrylpiperidine or trans-2, 
6-di-trans-styrylpiperidine and derivatives thereof in treat 
ing diseases or pathologies of the CNS is implicated. In 
particular, the treatment of dependencies on such drugs as 
cocaine, amphetamine, caffeine, nicotine, phencyclidine, 
opiates, barbiturates, benZodiaZepines, cannabinoids, 
hallucinogens, and alcohol is implicated. Also, the treatment 
of eating disorders such as obesity is implicated. 
In a preferred aspect of the invention, the method of 
treatment reduces an individual’s desire for the drug of 
abuse or for food by at least one day, but it is also preferred 
that the treatment method further comprises administering 
behavior modi?cation counseling to the individual. 
Although the compound of the present invention is contem 
plated primarily for the treatment of drug abuse and With 
draWal and for eating disorders, other uses are also sug 
gested by the studies discussed herein. Thus, cognitive 
disorders, brain trauma, memory loss, psychosis, sleep 
disorders, obsessive compulsive disorders, panic disorders, 
myasthenia gravis, Parkinson’s disease, AlZheimer’s 
disease, schiZophrenia, Tourette’s syndrome, Huntington’s 
disease, attention de?cit disorder, hyperkinetic syndrome, 
chronic nervous exhaustion, narcolepsy, pain, motion sick 
ness and depression, and related conditions are considered to 
be susceptible to treatment With a compound of the present 
invention. 
As shoWn by the results of the studies described herein, 
cis-2,6-di-trans-styrylpiperidine and trans-2,6-di-trans 
styrylpiperidine are found to be effective in inhibiting uptake 
of extracellular 5-HT by serotonergic nerve terminals in the 
CNS, as Well as in inhibiting the binding of [3H]MTBZ to 
vesicle membranes indicating an interaction With VMAT2. 
These analogs are also nicotinic receptor antagonists, inhib 
iting nicotine-evoked [3H]DA and [3H]NE release from rat 
brain slices. Either or both mechanisms can thereby alter the 
distribution of the intracellular neurotransmitter pools, and 
as a result, alter extracellular neurotransmitter concentra 
tions. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The 2,6-disubstituted piperidine analogs of the present 
invention include those contemplated by the folloWing for 
mula (I), Without regard to chirality: 
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R3 / 
wherein: 
R1 represents a hydrogen, methyl, deuteromethyl (CD3), 
tritiomethyl (CT3), ethyl, or C3—C7 straight chain or 
branched alkyl (preferably methyl or ethyl), C3—C6 
cycloalkyl, vinyl, allyl, C4—C7 alkenyl (including cis and 
trans geometrical forms), benZyl, and phenylethyl. 
R2 and R3 are each independently ortho-, meta-, orpara 
substituted moieties, where the substituent is described as 
hydrogen, methyl, ethyl, or C3—C7 straight chain or 
branched alkyl, C3—C6 cycloalkyl, vinyl, allyl, C4—C7 alk 
enyl (including cis and trans geometrical forms), benZyl, and 
phenylethyl. Further, the substitute moieties can be 
N-methylamino, N,N-dimethylamino, carboXylate, 
methylcarboXylate, ethylcarboXylate, propylcarboXylate, 
isopropylcarboXylate, carboXaldehyde, acetoXy, 
propionyloXy, isopropionyloXy, cyano, aminomethyl, 
N-methylaminomethyl, N,N-dimethylaminomethyl, 
carboXamide, N-methylcarboXamide, N,N 
dimethylcarboXamide, acetyl, propionyl, formyl, benZoyl, 
sulfate, methylsulfate, hydroXyl, methoXy, ethoXy, propoXy, 
isopropoXy, thiol, methylthio, ethylthio, propiothiol, ?uoro, 
chloro, bromo, iodo, tri?uoromethyl, propargyl, nitro, 
carbamoyl, ureido, aZido, isocyanate, thioisocyanate, 
hydroXylamino, and nitroso. 
The above 2,6-substituted piperidino analogs are pre 
ferred in their 2,6-cis geometrical isomeric forms, or in their 
2,6-trans geometric forms, including all possible geometric, 
racemic, diasteriomeric, and enantiomeric forms thereof. 
The above 2,6-disubstituted piperidines as well as their 
analogs can be administered in their free base form or as a 
soluble salt. Whenever it is desired to employ a salt of a 
2,6-substituted piperidine or its analog, it is preferred that a 
soluble salt be employed. Some preferred salts include 
hydrochloride, hydrobromide, nitrate, sulfate, phosphate, 
tartrate, galactarate, fumarate, citrate, maleate, glycolate, 
malate, ascorbate, lactate, aspartate, glutamate, 
methanesulfonate, p-toluenesulfonate, benZenesulfonate, 
salicylate, proprionate, and succinate salts. The above salt 
forms may be in some cases hydrates or solvates with 
alcohols and other solvents. 
Apharmaceutical composition containing a compound of 
the invention is also contemplated, which may include a 
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phosphates, carbonates, citrates and the like. Exemplary 
preservatives include EDTA, EGTA, BHA, BHT and the 
like. Acomposition of the invention may be administered by 
inhalation, i.e., intranasally as an aerosol or nasal formula 
tion; topically, i.e., in the form of an ointment, cream or 
lotion; orally, i.e., in solid or liquid form (tablet, gel cap, 
time release capsule, powder, solution, or suspension in 
aqueous or non aqueous liquid; intravenously as an infusion 
or injection, i.e., as a solution, suspension or emulsion in a 
pharmaceutically acceptable carrier; transdermally, e.g., via 
a transdermal patch; rectally as a suppository and the like. 
Generally, the pharmacologically effective dose of a 
present compound is in the amount ranging from about 
1><10_5 to about 1 mg/kg body weight/day. The amount to be 
administered depends to some eXtent on the lipophilicity of 
the speci?c compound selected, since it is eXpected that this 
property of the compound will cause it to partition into fat 
deposits of the subject. The precise amount to be adminis 
tered can be determined by the skilled practitioner in view 
of desired dosages, side effects and medical history of the 
patient and the like. 
The 2,6-disubstituted piperidino analogs of the present 
invention exhibit activity at either nAChRs and/or the sero 
tonin transporter protein (SERT) and/or the vesicular 
monoamine transporter (VMATZ). 
Compound 1 
\ \\““‘v N "ll'lll/ 
CH3 
Cis-Z,6-di-trans-styrylpiperidine 
Compound 2 
N 
CH3 
Trans—2,6—di—trans-styrylpiperidine 
Table 1 below summariZes the interaction of cis-2,6-di 
trans-styrylpiperidine (Compound 1) and trans-2,6-di-trans 
styrylpiperidine (Compound 2) with nicotinic receptors, 
SERT and VMAT2. 
TABLE 1 
Inhibition 
Nicotine- Inhibition of Inhibition of 
[3H]Nicotine [3H]MLA Evoked 86RB+ Nicotine- Nicotine- Inhibition of [3H]5—HT 
Binding Binding E?lux“ Evoked[3H]DA Evoked[3H]NE [3H]MTBZ Uptake 
(ICSU) Over?ow b(ICSU) Over?ow b(ICSO) binding (ICSU) (ICSU) 
Compound (1452* (17* (1452* (1352* (1354* vMAT2 SERT 
1 11 ,uM >100 ,uM >10 ,uM 0.03 ,uM 0.021 1.29 ,uM 23.2 ,uM 
2 13 ,uM >100 ,uM Not 0.54 ,uM Not 5.15 ,uM 1.19 ,uM 
determined determined 
3Inhibition of 1 ,uM S(—)—nicotine 
bInhibition of 10 ,uM S(—)—nicotine 
conventional additive, such as a stabiliZer, buffer, salt, 
preservative, ?ller, ?avor enhancer and the like, as known to 
those skilled in the art. Representative buffers include 
65 The two 2,6-disubstituted piperidino derivatives in Table 
1 have the chemical structure of Formula I, and were 
assayed for interaction with 0146*, 017*, (x3[32*and 
US 6,703,406 B2 
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(x3[34*subtypes of nAChRs, interaction With VMAT2 
located on vesicle membranes and inhibition of SERT func 
tion. It shall be noted that the nAChR subtypes for the 
activities described herein have not been elucidated 
conclusively, and thus, the asterisk is an indication of the 
putative nature of the receptor subtype mediating the action. 
Compound 1 exhibits good selectivity (43-fold) for the 
(x3[32*subtype of nAChR relative to its interaction With the 
MTBZ site on VMAT2, as indicated by its ability to inhibit 
nicotine-evoked [3H]DA release. Moreover, Compound 1 
exhibits very good selectivity (>370-fold) for the (x3[32*and 
(x3[34*subtypes of nAChRs compared to its interaction With 
either (x4[32*or ot7*subtypes of nAChR. Furthermore, Com 
pound 1 Was 770-fold more selective as an inhibitor of the 
(x3[32*and (x3[34*subtypes of nAChR compared to its inhi 
bition of SERT function. Finally, Compound 1 interacted 
With VMAT2 18-fold more selectively than it inhibited the 
function of SERT. 
Compound 2 Was also assayed for interaction With 
nAChRs subtypes, interaction With VMAT2 located on 
vesicle membranes and inhibition of SERT function. Com 
pound 2 exhibits good selectivity (9.5-fold) for the 
(x3[32*subtype of nAChR relative to its interaction With the 
MTBZ site on VMAT2, as indicated by its ability to inhibit 
nicotine-evoked [3H]DA release. Moreover, Compound 2 
exhibits very good selectivity (>24-fold) for the (x3[32*sub 
type of nAChR compared to its interaction With either 
(x4[32*or ot7*subtypes of nAChR. Furthermore, Compound 
2 Was only 2.2-fold more selective as an inhibitor of the 
(x3[32*subtypes of nAChR compared to its inhibition of 
SERT function. Finally, Compound 2 interacted With SERT 
43-fold more selectively than it interacted With VMAT 2. 
Compound 1 Was 18-fold more potent at inhibiting 
nicotine-evoked [3H]DA and [3H]NE release from rat stri 
atal and hippocampal slices, indicated a higher affinity for 
the (x3[32*and (x3[34*subtypes of nAChRs, compared to 
Compound 2. On the other hand, Compound 2 Was 19-fold 
more potent inhibiting the function of SERT than Was 
Compound 1. Finally, Compound 1 Was only 4-fold more 
potent interacting With VMAT2 compared to Compound 2. 
Thus, alteration of stereochemistry at C2 and C6 from cis to 
trans resulted in a diminished affinity for the (x3[32*subtypes 
of nAChR and for VMAT2, and enhanced the affinity for 
SERT, Whereas there Was no change in affinity for either 
(x4[32*or ot7*subtypes of nAR. Therefore, cis-analogs have 
higher affinity for VMAT2 and (x3[32*subtype of nAChRs. 
The invention Will noW be discussed by certain examples 
Which illustrate but do not limit the invention. 
EXAMPLE 1 
Scheme 1: Synthesis of cis- and trans-2,6-di-trans-styrylpiperidine 
Preparation of Cis- and trans-2,6-di-trans-styrylpiperidine 
OH 0 
‘_.~ -.,I NaBH4 
\\\\ N 1,1! —> 
I ethanol 
CH3 
1/2 H2504 
Lobeline 
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6 
-continued 
OH O OH 
CH3 
Lobelanidine 
CH3 
Cis-2,6-di-trans-styrylpiperidine 
CH3 
Trans-2,6-di-trans-styrylpiperidine 
To a suspension of L-lobeline hemisulfate salt (85%, 10.5 
g) in absolute ethanol (300 mL) Was added NaBH4 (1.5 eq.) 
portionWise at 0° C. The mixture Was stirred at 0° C. for 1 
h, and then quenched With acetone. The mixture Was evapo 
rated under reduced pressure. Water (100 mL) Was added to 
the residue and extracted With chloroform (80 mL><3). The 
combined organic extract Was dried (MgSO4), ?ltered and 
evaporated to afford lobelanidine as a White solid Which Was 
used directly. An analytical sample Was recrystalliZed from 
acetone/hexane as a needle crystal. Mp 142—143° C; 1H 
NMR (300 MHZ, CDCl3) 6 1.15 (m, 2H), 1.44—1.82 (m, 
6H), 2.04 (ddd, J=14.4, 10.2, 8.7 HZ, 2H), 2.35 (s, 3H), 2.96 
(m, 2H), 4.89 (dd, J=8.7, 5.5 HZ, 2H), 7.23—7.50 (m, 10H); 
13C NMR (75 MHZ, CDCl3) 6 23.48, 25.20, 25.96, 41.79, 
62.37, 74.30, 125.98, 127.50, 128.55, 144.88 ppm. 
Crude lobelanidine Was dissolved in 130 mL 85% H3PO4 
and alloWed to stir at 60° C. for 24 h. The reaction mixture 
Was cooled to room temperature, diluted With 250 mL Water 
and made basic With solid NaOH (pH~10). The aqueous 
solution Was extracted With EtOAc (150 mL><3) The com 
bined organic extract Was dried (MgSO4), ?ltered and con 
centrated under reduced pressure. The crude product Was 
recrystalliZed from acetone affording 2.2 g of pure cis-2,6 
di-trans-styrylpiperidine as a White solid. Mp: 105—106° C. 
(HCl salt); 1H NMR (300 MHZ, CDCl3) 6 1.42—1.88 (m, 
6H), 2.25 (s, 3H), 2.63 (m, 2H), 6.21 (dd, J=15.9, 9.0, 2H), 
6.51 (d, J=15.9, 2H), 7.19—7.41 (m, 10H); 13C NMR (75 
MHZ, CDCl3) 6 24.14, 33.94, 42.61, 68.56, 126.32, 127.46, 
128.69, 130.51, 134.03, 137.17 ppm. The remaining mother 
liquor Was evaporated and the residue Was chromatographed 
(SiO2, EtOAc/hexanes, 1/10) to afford cis-2,6-di-trans 
styrylpiperidine 1.4g and trans-2S,6S-di-trans 
styrylpiperidine 230 mg. Mp: 200—202° C. (HCl salt); 1H 
NMR (300 MHZ, CDCl3) 6 1.60—1.75 (m, 4H), 1.82—1.97 
(m, 2H), 2.27 (s, 3H), 3.38 (m, 2H), 6.38 (dd, J=15.9, 8.7, 
2H), 6.52 (d, J=15.9, 2H), 7.17—7.42 (m, 10H); 13C NMR 
(75 MHZ, CDCl3) 6 19.57, 32.92, 41.96, 62.29, 126.39, 
127.50, 128.69, 130.49, 131.78, 137.20 ppm. 
EXAMPLE 2 
High Affinity [3H]Nicotine Binding Assay 
The ability to displace S(—)[3H]nicotine binding from rat 
striatal membranes Which assessed the (x4[32*subtype Was 
US 6,703,406 B2 
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determined. The [3H]nicotine binding assay Was performed 
according to previously published methods (Romano et al., 
1980; Marks et al., 1986; Crooks et al., 1995). Striata from 
tWo rats Were dissected, pooled and homogenized With a 
Tekmar polytron in 10 vol of ice-cold modi?ed Krebs 
HEPES buffer (20 mM HEPES, 118 niM NaCl, 4.8 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, adjusted to pH to 7.5). 
The homogenate Was incubated at 37° C. for 5 min to 
promote hydrolysis of endogenous acetylcholine, and cen 
trifuged at 27,000 g for 20 min and the pellet Was resus 
pended in 10 vol of ice-cold distilled Water and incubated at 
37° C. for 5 min, folloWed by centrifugation at 27,000 g for 
20 min. The pellet containing the striatal membranes Was 
resuspended in 10 vol of fresh ice-cold 10% Krebs-HEPES 
buffer and incubated at 37° C. for 10 min after Which it Was 
centrifuged at 27,000 g for 20 min. The latter sequence of 
resuspension, incubation and centrifugation Was repeated. 
The pellet Was froZen under fresh Krebs-HEPES buffer and 
stored at —40° C. until assay. Upon assay, the pellet Was 
resuspended in Krebs-HEPES buffer, incubated at 37° C. for 
5 min and centrifuged at 27,000 g for 20 min. The ?nal pellet 
Was resuspended in 3.6 mL ice-cold Water, Which provides 
for approximately 200 pg protein/100 pL aliquot, as de?ned 
by the Bradford dye binding method (Bradford, 1976) using 
bovine serum albumin (BSA) as the standard. Competition 
assays Were performed in duplicate in a ?nal vol of 200 pL 
Krebs-HEPES buffer containing 250 mM Tris buffer (pH 7.5 
at 4° C.). Reactions Were initiated by addition of 100 pL of 
membrane suspension to 3 nM [3H]nicotine (L-(—)-[N 
methyl-3H]nicotine; 50 pL, speci?c activity 69.5 Ci/mMol) 
and 1 of at least 9 concentrations of analog (50 ML). After a 
90 min incubation at 4° C., reactions Were terminated by 
dilution of the samples With 3 mL of ice-cold buffer folloWed 
immediately by ?ltration through a Whatman GF/B glass 
?ber ?lters (presoaked in 0.5% polyethyleneimine using a 
Brandel cell harvester). Filters Were rinsed 3 times With 3 
mL of ice-cold buffer, transferred to scintillation vials and 5 
mL scintillation cocktail added. Nonspeci?c binding Was 
de?ned as binding in the presence of 10 pM S(—)-nicotine. 
For competition curves, the IC5O values Were corrected for 
ligand concentration to obtain Ki values for each analog 
(Cheng et al., 1973). 
EXAMPLE 3 
[3H]Methyllycaconitine ([°]HIMLA)Binding Assay 
Whole rat brain (minus cortex, striatum and cerebellum) 
Was homogeniZed in 20 vol of ice-cold hypotonic buffer (2 
mM HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2 
and 0.1 mM MgSO4, pH 7.5). Homogenates Were incubated 
at 37° C. for 10 min and centrifuged at 25,000 g for 15 min 
at 4° C. Pellets Were Washed 3 times by resuspension in 20 
vol of the same buffer and centrifugation using the above 
parameters. Final pellets Were resuspended in incubation 
buffer to provide ~150 pg protein/100 pL. Binding assays 
Were performed in duplicate, in a ?nal vol of 250 pL 
incubation buffer, containing 20 mM HEPES, 144 mM 
NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and 0.05% 
BSA, pH 7.5. Assays Were initiated by the addition of 100 
pL membrane suspension to 150 ML of sample containing 2.5 
nM [3H]MLA ([1ot, 4(S), 6B, 1401, 16[3]-20-ethyl-1,6,14,16 
tetramethoxy-4[[[2-(-[3-3H]-methyl-2,5-dioxo-1 
pyrrolidinyl)benZoyl]oxy]methyl]aconitane-7,8-diol; spe 
ci?c activity 26.2 Ci/mMol) and at least 6 concentrations (30 
nM—100 pM) synthetic analog (?nal concentrations), and 
incubated for 2 h at room temperature. Nonspeci?c binding 
Was determined in the presence of 10 pM MLA. Assays Were 
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terminated by dilution of samples With 3 mL ice-cold 
incubation buffer folloWed by immediate ?ltration through 
Schleicher & Schuell #32 glass ?ber ?lters (Keene, NH; 
presoaked With 0.5% PEI) using the cell harvester. Filters 
Were rinsed 3 times With 3 mL of ice-cold buffer, transferred 
to scintillation vials, 4 mL of scintillation cocktail added, 
and bound radiolabel determined by liquid scintillation 
spectroscopy. Protein Was measured using the Bradford 
dye-binding method (Bradford, 1976) With BSA as the 
standard. 
EXAMPLE 4 
[3H]MethoxytetrabenaZine [3H]MTBZ Binding 
Assay 
Synaptic vesicles Were prepared from rat brain using a 
modi?cation of a previously described procedure (Teng et 
al., 1998). Brie?y, fresh Whole brain (excluding cerebellum) 
Was homogeniZed using a Te?on pestle (clearance 0.003 
mm) With 7 vertical strokes at 800 rpm in 20 vol of ice-cold 
0.32 M sucrose and centrifuged at 1000 g for 12 min at 4° 
C. The resulting supernatant (S1) Was then centrifuged at 
22,000 g for 10 min at 4° C. The synaptosomal pellets (P2) 
Were homogeniZed in 18 mL of ice-cold Milli-Q Water and 
exposed for 5 min for lysing synaptosomes. Osmolarity Was 
restored by addition of 2 mL of 25 mM HEPES With 100 
mM dipotassium tartrate (pH 7.5). Samples Were centrifuged 
at 20,000 g for 20 min at 4° C. to remove lysed synaptoso 
mal membranes. MgSO4 (1 mM) Was added to the super 
natant (S3), and Was centrifuged at 100,000 g for 45 min at 
4° C. The ?nal vesicular pellets (P4) Were resuspended in 
ice-cold assay buffer (see beloW) providing ~15 pg protein/ 
100 ML, determined by the method of Bradford (1976) using 
bovine serum albumin as a the standard. Aliquot parts (100 
ML) of suspension of vesicle membrane protein Were incu 
bated in assay buffer (25 mM HEPES, 100 mM dipotassium 
tartrate, 5 mM MgSO4, 0.1 mM EDTA and 0.05 mM EGTA, 
pH 7.5, at 25° C.) in the presence of 3 nM [°H]MTBZ 
([O-methyl -°H]methoxytetrabenaZine) and at least 7 con 
centrations (1 nM—1 mM) of analog for 1 hr at room 
temperature. Nonspeci?c binding Was determined in the 
presence of 20 pL TBZ. Assays Were performed in duplicate 
using a 96-Well plate format. Reactions Were terminated by 
?ltration of samples on a Uni?lter-96 GF/B ?lter plates 
(presoaked in 0.5% polyethylenimine), using a FilterMate 
harvester (Packard BioScience Co., Meriden, Conn.). After 
Washing 5 times With 350 ML of the ice-cold Wash buffer (25 
mM HYEPES, 100 mM dipotassium tartrate, 5 mM MgSO4 
and 10 mM NaCl, pH 7.5), ?lter plates Were dried, sealed 
and each Well ?lled With 40 pL Packard’s MicroScint 20 
cocktail. Bound [°H]MTBZ Was measured using a Packard 
TopCount NXT scintillation counter With a Packard Win 
doWs NT based operating system. 
EXAMPLE 5 
[3H]5-HT Uptake Assay 
[3H]5-HT uptake Was assessed using modi?cations of a 
previously described method (Teng et al., 1998). Nonspe 
ci?c uptake Was determined in duplicate samples in the 
presence of excess (10 pM) ?uoxetine. Rat hippocampus 
Was homogeniZed in 20 mL cold 0.32 M sucrose containing 
5 mM NaHCO3 (pH 7.4) With 12 vertical strokes of a Te?on 
pestle homogeniZer (clearance~0.015 The homoge 
nate Was centrifuged (2,000><g for 10 min at 4° C.). The 
supernatant Was centrifuged (20,000><g for 15 min at 4° C.), 
and then the pellet Was resuspended in 1.5 mL of Kreb’s 
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buffer (125 rnM NaCl, 5 rnM KCl, 1.5 rnM MgSO4, 1.25 
rnM CaCl2, 1.5 rnM KH2PO4, 10 rnM ot-D-glucose, 25 rnM 
HEPES, 0.1 rnM disodiurn ethylenediarnine tetraacetate, 0.1 
rnM pargyline and 0.1 rnM ascorbic acid, saturated With 
95% O2/5% CO2, pH 7.4). Final protein concentration Was 
400 pg/rnL, determined using BSA standard (Bradford, 
1976). The assay Was performed in duplicate in a total vol 
of 500 pL. Aliquot parts of synaptosornal suspension (50 ML) 
Were added to tubes containing 350 pL Kreb’s buffer and 50 
pL of buffer containing 1 of 9 concentrations of analog. 
Tubes Were preincubated at 34° C. for 10 min before 
addition of 50 ML of [3H]5-HT (5-[1,2-3H(N)] 
hydroXytryptarnine; speci?c activity 25.5 Ci/rnMol, ?nal 
concentration 10 nM). Accurnulation proceeded for 10 min 
at 34° C. Reactions were terminated by addition of 3 rnL 
ice-cold Kreb’s buffer. Samples were rapidly ?ltered 
through a Whatrnan GF/B ?lter using a cell harvester 
(MP-43RS, Brandel Inc., Gaithersburg, Md.), and the ?lter 
Was subsequently Washed 3 times With 4 rnL ice-cold Kreb’s 
buffer containing catechol (1 rnM). Filters Were previously 
soaked for 2 hours in the ice-cold Kreb’s buffer containing 
catechol (1 rnM). Radioactivity on ?lters was determined by 
liquid scintillation spectroscopy. 
EXAMPLE 6 
[3H]Doparnine and [3H]Norepineplhrine Release 
Assay 
Alkaloid effects on [3H]over?oW from rat striatal slices 
preloaded With [3H]DA and hippocarnpal slices preloaded 
With [3H]NE were determined using rnodi?cations of a 
previously published rnethod (DWoskin and Zahniser, 1986). 
Brie?y, coronal striatal or hippocampal slices (500 urn, 6—8 
mg) Were incubated in Krebs’ buffer (118 rnM NaCl, 4.7 
rnM KCl, 1.2 rnM MgCl2, 1.0 rnM NaH2PO4, 1.3 rnM 
CaCl2, 11.1 rnM ot-D-glucose, 25 rnM NaHCO3, 0.11 rnM 
L-ascorbic acid and 4.0 rnM disodiurn ethylenediarninetet 
raacetate; pH 7.4, and saturated With 95% O2/5% CO2) in a 
metabolic shaker at 34° C. for 30 rnin. Striatal or hippoc 
arnpal slices Were incubated in fresh buffer (6—8 slices/3 rnL) 
containing 0.1 MM [3H]DA (3,4-[7-3H] 
dihydroXyphenylethylarnine; speci?c activity 28 Ci/rnMol) 
or 0.1 pM [3H]NE (levo-[7-3H]-norepinephrine; speci?c 
activity 14.4 Ci/rnMol), respectively, for an additional 30 
min. After rinsing, each slice Was transferred to a glass 
superfusion charnber maintained at 34° C. and Was super 
fused at 1 rnL/rnin With oXygenated Krebs’ buffer containing 
pargyline (10 pM) and nornifensine (10 pL) or pargyline and 
desiprarnine (10 pL) in experiments assessing [3H]DA and 
[3H]NE over?oW, respectively. After 60 min of superfusion, 
three 5-rnin samples (5 rnL) Were collected to determine 
basal [3H]out?oW. After collection of the third basal sarnple, 
slices from an individual rat Were superfused in the absence 
or presence of a single concentration of analog, which 
remained in the buffer until the end of the experiment. Each 
slice Was eXposed to only one concentration of analog. After 
30 rnin, S(—)-nicotine (10 pM) Was added to the buffer 
containing analog, and superfusion continued for an addi 
tional 60 rnin. These experiments utiliZed a repeated mea 
sures design, such that the analog concentration-effect was 
determined in both the absence and presence of S(—) 
nicotine using striatal or hippocarnpal slices from a single 
rat. Additionally, one striatal or hippocarnpal slice Was 
superfused in the absence of analog and constituted the 
control condition. At the end of the experiment, each slice 
Was solubiliZed With TS-2. The pH and volume of the 
solubiliZed tissue samples Were adjusted to those of the 
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superfusate sarnples. Radioactivity in the superfusate and 
tissue samples was determined by liquid scintillation spec 
troscopy (Packard rnodel B1600 TR Scintillation Counter, 
DoWner’s Grove, Ill.). 
EXAMPLE 7 
86Rb+ Rubidiurn Ef?uX Assay 
Analog effects on 8° Rb+ efflux were determined using a 
previously published rnethod (Miller et al., 2000). Thalarnus 
was homogenized and centrifuged at I1000><g for 10 min at 
4° C. The supernatant fraction Was centrifuged at 12,000><g 
for 20 min at 4° C. to obtain the synaptosornal fraction. 
Synaptosornes Were incubated for 30 min in 35 ML of uptake 
buffer (1.40 rnM NaCl, 1.5 rnM KCl, 2.0 rnM CaCl2, 1.0 
rnM MgSO4, 20 rnM ot-D-glucose; pH 7.5) containing 4 pCi 
of 86Rb". 86Rb+ uptake was terminated by ?ltration of the 
synaptosornes onto glass ?ber ?lters (6 mm; Type A/E, 
Gelrnan Sciences, Ann Arbor, Mich.) under gentle vacuurn 
(0.2 atrn), folloWed by three Washes With superfusion buffer 
(0.5 rnL each). Subsequently, each ?lter With 86Rb"-loaded 
synaptosornes (40 pg protein/pl) Was placed on a 13 mm 
glass ?ber ?lter (Type A/F) mounted on a polypropylene 
platforrn. 86Rb+ ef?uX assay buffer (125 rnM NaCl, 5 rnM 
CsCl, 1.5 rnM KCl; 2 rnM CaCl2, 1 rnM MgSO4, 25 rnM 
HEPES, 20 rnM ot-D-glucose, 0.1 pM tetrodotoXin, 1.0 g/L 
bovine serum albumin; pH 7.5) Was superfused onto the 
synaptosornes at a rate of 2.5 rnL/rnin. TetrodotoXin and 
CsCl Were included in the buffer to block voltage-gated Na+ 
and K+ channels, respectively, and to reduce the rate of basal 
86Rb+ ef?uX. The ability of analogs to inhibit 86Rb+ efflux 
evoked by 1 pM nicotine was determined. After 8 min of 
superlusion, samples were collected (sarnple/18 s) for 5 min 
to determine basal 86Rb+ ef?uX. Subsequently, synapto 
sornes Were superfused for 3 min With analog folloWed by 
superfusion With buffer containing analog and nicotine for 
an additional 3 min. Each aliquot part of thalarnic synapto 
sornes Was eXposed to only one concentration of analog. In 
each experiment, one synaptosornal aliquot part Was super 
fused in the absence of analog to determine basal 8°Rb+ 
ef?uX over the course of the superfusion period, and another 
aliquot part Was superfused With nicotine (1 pM) to deter 
mine the effect of nicotine on 86Rb+ efflux in the absence of 
analog. Samples were analyZed by liquid scintillation spec 
troscopy (Packard rnodel B1600 TR Scintillation Counter). 
The foregoing is considered as illustrative only of the 
principles of the invention. Further, since nurnerous rnodi 
?cations and changes Will readily occur to those skilled in 
the art, it is not desired to limit the invention to the eXact 
construction and operation shoWn and described, and 
accordingly, all suitable rnodi?cations and equivalence 
thereof may be resorted to, falling Within the scope of the 
invention claimed. 
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What is claimed is: 
1. A method of treating an individual for dependence on 
or WithdraWal from a drug of abuse, for an eating disorder 
or for a CNS disease or pathology, comprising the step of 
administering to the individual an effective amount of a 
2,6-substituted piperidino compound and pharmaceutically 
effective salts thereof, including resolved diasteriomers, 
enantiomers thereof, of the formula (I): 
12 
(1) 
R3 / — R2 
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R1 
10 Wherein: 
R1 represents a hydrogen, methyl, deuteromethyl (CD3), 
tritiomethyl (CT3), ethyl, or C3—C7 straight chain or 
branched alkyl, C3—C6 cycloalkyl, vinyl, allyl, C4—C7 
alkenyl, benZyl, and phenylethyl; 
R2 and R3 are each independently ortho-, meta-, or 
para-substituted moieties, Where the substituted moiety 
is selected from the group consisting of hydrogen, 
methyl, ethyl, C3—C7 straight chain or branched alkyl, 
C3—C6 cycloalkyl, vinyl, allyl, C 4—C7 alkenyl, benZyl, 
phenylethyl, N-methylamino, N,N-dimethylamino, 
carboXylate, methylcarboXylate, ethylcarboXylate, 
propylcarboXylate, isopropylcarboXylate, 
carboXaldehyde, acetoXy, propionyloXy, 
isopropionyloXy, cyano, aminomethyl, 
N-methylaminomethyl, N,N-dimethylaminomethyl, 
carboXamide, N-methylcarboXamide, N,N 
dimethylcarboXamide, acetyl, propionyl, formyl, 
benZoyl, sulfate, methylsulfate, hydroXyl, methoXy, 
ethoXy, propoXy, isopropoXy, thiol, methylthio, 
ethylthio, propiothiol, ?uoro, chloro, bromo, iodo, 
2O 
25 
30 
tri?uoromethyl, propargyl, nitro, carbamoyl, ureido, 
aZido, isocyanate, thioisocyanate, hydroXylamino, and 
nitroso. 
2. The method of claim 1, Wherein R1 is methyl or ethyl. 
3. The method of claim 1, Wherein R1 is methyl. 
4. The method of claim 1, Wherein the 2,6-substituted 
piperidino compound or pharmaceutically effective salt 
thereof is cis-2,6-di-trans-styrlpiperidine having the folloW 
ing formula (II): 
| 
CH3 
35 
45 
5. The method of claim 1, Wherein the 2,6-substituted 
piperidino compound or pharmaceutically effective salt 
thereof is trans-2,6-di-trans-styrlpiperidine having the fol 
loWing formula (II): 
CH3 
6. The method of claim 1 Wherein said drug of abuse is 
65 selected from the group consisting of cocaine, amphetamine, 
caffeine, nicotine, phencyclidine, opiates, barbiturates, 
benZodiaZepines, canabinoids, hallucinogens and alcohol. 
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7. The method of claim 1 wherein in said CNS disease or 
pathology is selected from the group consisting of cognitive 
disorders, brain trauma, memory loss, psychosis, depression, 
sleep disorders, obsessive compulsive disorders, panic 
disorders, myasthenia gravis, Parkinson’s disease, AlZhe 
imer’s disease, schiZophrenia, Tourette’s syndrome, Hun 
tington’s disease, attention de?cit disorder, hyperkinetic 
syndrome, chronic nervous exhaustion, narcolepsy, motion 
sickness and the control of pain. 
8. The method of claim 1 Wherein said 2,6-substituted 
piperidino compound or pharmaceutically effective salt 
10 
14 
thereof is administered subcutaneously, intramuscularly, 
intravenously, transdermally, orally, intranasally, intrapul 
monary or rectally. 
9. The method of claim 1 Wherein said 2,6-substituted 
piperidino compound or pharmaceutically effective salt 
thereof inhibits release, uptake and storage of DA, NE and 
5-HT by cells of the central nervous system of the indi 
vidual. 
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